Reduced NGF serum levels and abnormal P300 event-related potential in first episode schizophrenia

Schizophrenia Research

Volumn 119, Issue 1-3, 2010, Pages 34-39

  Xiong, Peng ^a,b   Zeng, Yong ^b   Zhu, Zuxin ^b   Tan, Deyong ^a   Xu, Fei ^b   Lu, Jin ^b   Wan, Jing ^b   Ma, Mingxing ^a  

^a YUNNAN UNIVERSITY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Event related potentials (ERP); First episode schizophrenia; Nerve growth factor (NGF); P300; Positive and Negative Syndrome Scale (PANSS)

Indexed keywords

NERVE GROWTH FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROENCEPHALOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; EVENT RELATED POTENTIAL; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; LATENT PERIOD; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOLOGIC ASSESSMENT; SCHIZOPHRENIA; SCORING SYSTEM;

ADOLESCENT; ADULT; CEREBRAL CORTEX; ELECTROENCEPHALOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVENT-RELATED POTENTIALS, P300; FEMALE; HUMANS; MALE; NERVE GROWTH FACTOR; NEURONAL PLASTICITY; PSYCHIATRIC STATUS RATING SCALES; REACTION TIME; REFERENCE VALUES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 77952660861     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.02.1063     Document Type: Article

References (73)

1. Aloe L., Iannitelli A., Bersani G., Alleva E., Angelucci F., Maselli P., Manni L. Haloperidol administration in humans lowers plasma nerve growth factor level: evidence that sedation induces opposite effects to arousal. Neuropsychobiology 1997, 36:65-68.
2. Angelucci F., Brene S., Mathe A.A. BDNF in schizophrenia, depression and corresponding animal models. Mol. Psychiatry 2005, 10:345-352.
3. Bersani G., Iannitelli A., Maselli P., Pancheri P., Aloe L., Angelucci F., Alleva E. Low nerve growth factor plasma levels in schizophrenic patients: a preliminary study. Schizophr. Res. 1999, 37:201-203.
4. Bibel M., Barde Y.A. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev. 2000, 14:2919-2937.
5. Blackwood D.H.R., Whalley L.J., Christie J.E., Blackburn I.M., St.Clair D.M., McInnes A. Changes in auditory P3 eventrelated potential in schizophrenia and depression. Br. J. Psychiatry 1987, 150:154-160.
6. Brown K., Gordon E., Williams L.M., Bahramali H., Harris A.W.F., Gray J.A., et al. Misattribution of sensory input reflected in dysfunctional target: Nontarget ERPs in schizophrenia. Psychol. Med. 2000, 30:1443-1449.
7. Brown K.J., Gonsalvez C.J., Harris A.W., Williams L.M., Gordon E. Target and non-target ERP disturbances in first episode vs. chronic schizophrenia. Clin. Neurophysiol. 2002, 113:1754-1763.
8. Chao M.V. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev. Neurosci. 2003, 4:299-309.
9. Connor B., Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res.Brain Res. Rev. 1998, 27:1-39.
10. Coull J.T. Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacology. Prog. Neurobiol. 1998, 55:343-361.
11. Demiralp T., Ucok A., Devrim M., Isoglu-Alkac U., Tecer A., Polich J. N2 and P3 components of event-related potential in first-episode schizophrenic patients:scalp topography, medication, and latency effects. Psychiatry Res. 2002, 111(2-3):167-179.
12. Donchin E., Coles M.G.H. Is the P300 component a manifestation of contextupdating. Behav. Brain Sci. 1988, 11:357-374.
13. Durany N., Michel T., Zochling R., Boissl K.W., Cruz-Sanchez F.F., Riederer P., Thome J. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 2001, 52:79-86.
14. Durany Nuria, Thome Johannes Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur. Psychiatry 2004, 19:326-337.
15. Eikmeier G., Lodemann E., Zerbin D., Gastpar M. P300, clinical symptoms, and neuropsychological parameters in acute and remitted schizophrenia: a preliminary report. Biol. Psychiatry 1992, 31:1065-1069.
16. Egan M.F., Duncan C.C., Suddath R.L., Kirch D.G., Mirsky A.F., Wyatt R.J. Event-related potential abnormalities correlate with structural brain alterations and clinical features in patients with chronic schizophrenia. Schizophr. Res. 1994, 11:259-271.
17. Frodl-Bauch T., Gallinat J., Meisenzahl E.M., Moeller H.J., Hegerl U. P300 subcomponents reflect different aspects of psychopathology in schizophrenia. Biol. Psychiatry 1999, 45(1):116-126.
18. Ford J.M., Pfefferbaum A., Roth W. P3 and schizophrenia. Ann. N. Y. Acad. Sci. 1992, 658:146-162.
19. Garofalo L., Ribeiro-da-Silva A., Cuello A.C. Nerve growth factor-induced synaptogenesis and hypertrophy of cortical cholinergic terminals. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:2639-2643.
20. Gould H.J., Gould T.N., England J.D., Paul D., Liu Z.P., Levinson S.R. Nerve growth factor enhances sodium channel expression in rat dorsal root ganglia. American Pain Society 1998, 17:104.
21. Gould H.J., Gould T.N., England J.D., Paul D., Liu Z.P., Levinson S.R. A possible role for nerve growth factor in the augmentation of sodium channels i. Brain Res 2000, 854:19-29.
22. Higashima M., Nagasawa T., Kawasaki Y., Oka T., Sakai N., Tsukada T., Koshino Y. Auditory P300 amplitude as a state marker for positive symptoms in schizophrenia: cross-sectional and retrospective longitudinal studies. Schizophr. Res. 2002, 59:147-157.
23. Hirayasu Y., Asato N., Ohta H., Hokama H., Arakaki H., Ogura C. Abnormalities of auditory event-related potentials in schizophrenia prior to treatment. Biol. Psychiatry 1998, 43:244-253.
24. Holdstock J.S., Rugg M.D. The effect of attention on the P300 deflection elicited by novel sounds. J. Psychophysiol. 1995, 9:18-31.
25. Kafitz K.W., Rose C.R., Thoenen H., Konnerth A. Neurotrophinevoked rapid excitation through Trk-B receptors. Nature 1999, 401:918-921.
26. Kawasaki Y., Maeda Y., Higashima M., Nagasawa T., Koshino Y., Suzuki M., Ide Y. Reduced auditory P300 amplitude, medial temporal volume reduction and psychopathology in schizophrenia. Schizophr. Res. 1997, 26:107-115.
27. Kay S., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-275.
28. Kok A. On the utility of P3 amplitude as a measure of processing capacity. Psychophysiology 2001, 38:557-577.
29. Korsching S., Auburger G., Heumann R., Scott J., Thoenen H. Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic enervation. EMBO J. 1985, 4:1389-1393.
30. Kromer L.F. Nerve growth factor treatment after brain injury prevents neuronal death. Science 1987, 235:214-216.
31. Leng J., et al. Brain-derived neurotrophic factor and electrophysiological properties of voltage-gated ion channels during neuronal stem cell development. Brain Res. 2009, 10.1016/j.barinres. 03.048.
32. Lesser S.S., Lo D.C. Regulation of voltage-gated ion channels by NGF and ciliary neurotrophic factor in SK-N-SH neuroblastoma cells. J. Neurosci. 1995, 15:253-261.
33. Levi-Montalcini R. The nerve growth factor 35years later. Science 1987, 237:1154-1162.
34. Levine E.S., Dreyfus C.F., Black I.B., Plummer M.R. Differential effects of NGF and BDNF on voltage-gated calcium currents in embryonic basal forebrain neurons. J Neurosci. 1995, 15:3084-3091.
35. Levit R.A., Sutton S., Zubin J. Evoked potential correlates of information processing in psychiatric patients. Psychol. Med. 1973, 3:487-494.
36. Liu Z., Tam W.-C.C., Xue Z., Yao S., Wu D. Positive and negative symptom profile schizophrenia and abnormalities in the P300 component of the event-related potential: a longitudinal controlled study. Psychiatry Res. 2004, 132:131-139.
37. Lo D.C. Neurotrophic factors and synaptic plasticity. Neuron 1995, 15:979-981.
38. Mahadik S.P., Evans D.R., Terry A., Hill W.D. Differential effects of risperidone and haloperidol on cognitive performance on rats and possible mechanism of action. Biol. Psychiatry 2001, 49:133S.
39. Mahadik S.P., Evans D.R., Terry A., Hill W.D. Neuroprotective action of atypical antipsychotics in schizophrenia: improved cognitive performance and underlying mechanism of action. Schizophr. Res. 2001, 49:94.
40. Mamet Julien, Lazdunski Michel, Voilley Nicolas How nerve growth factor drives physiological and inflammatory expressions of acid-sensing ion channel 3 in sensory neurons. J. Biol. Chem. 2003, 278:48907-48913.
41. Martin-Loeches M., Molina V., Munoz F., Hinojosa J.A., Reig S., Desco M. Benito a possible correlate of frontal degeneration in schizophrenia. Schizophr. Res. 2001, 49:121-128.
42. Mathalon D.H., Ford J.M., Pfefferbaum A. Trait and state aspects of P300 amplitude reduction in schizophrenia: a retrospective longitudinal study. Biol. Psychiatry 2000, 47:434-449.
43. McCarley R.W., Faux S.F., Shenton M., LeMay M., Cane M., Ballinger R., Duffy F.H. CT abnormalities in schizophrenia: a preliminary study of their correlations with P300/P200 electrophysiological features and positive/negative symptoms. Arch. Gen. Psychiatry 1989, 46:698-708.
44. McCarley R.W., Faux S.F., Shenton M.E., Nestor P.G., Adams J. Event-related potentials in schizophrenia: their biological and clinical correlates and a new model of schizophrenic pathophysiology. Schizophr. Res. 1991, 4:209-231.
45. McCarley R.W., Salisbury D.F., Hirayasu Y., Yurgelun-Todd D.A., Tohen M., Zarate C., et al. Association between smaller left posterior superior temporal gyrus volume on magnetic resonance imaging and smaller left temporal P300 amplitude in firstepisode schizophrenia. Arch. Gen. Psychiatry 2002, 59:321-331.
46. McCarley R.W., Shenton M.E., O'Donnell B.F., Faux S.F., Kikinis R., Nestor P.G., Jolesz F.A. Auditory P300 abnormalities and left posterior superior temporal Gyrus volume reduction in schizophrenia. Arch. Gen. Psychiatry 1993, 50:190-197.
47. Miao Aihong, Liu Xiaoling, Lü Shujuan Efficacy of nerve growth factor on the treatment of optic nerve contusion: evaluation with visual evoked potential. Neural Regen. Res. 2007, 2(9):121-127.
48. Nockher W.A., Renz H. Neurotrophins in allergic diseases: from neuronal growth factors to intercellular signaling molecules. J. Allergy Clin. Immunol. 2006, 117:583-589.
49. O'Donnell B.F., McCarley R.W., Potts G.F., Salisbury D.F., Nestor P.G., Hirayasu Y., Niznikiewicz M.A., Barnard J., Shen Z.J., Weinstein D.M., Bookstein F.L., Shenton M.E. Identification of neural circuits underlying P300 abnormalities in schizophrenia. Psychophysiology 1999, 36:388-398.
50. O'Donnell B.F., Shenton M.E., McCarley R.W., Faux S.F., Smith R.S., Salisbury D.F., Nestor P.G., Pollak S.D., Kikinis R., Jolesz F.A. The auditory N2 component in schizophrenia: relationship to MRI temporal lobe gray matter and to other ERP abnormalities. Biol. Psychiatry 1993, 34:26-40.
51. Orloval V., Efanova1 N., Tshcherbakova1 I., Klushnik1 T. MRI - Peculiarities of frontal lobes and auto antibodies to nerve growth factor (NGF) in families of patients with schizophrenia Abstracts. Schizophrenia Res. 2008, 98:3-199.
52. Parikh V., Evans D.R., Khan M.M., Mahadik S.P. Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: possible implications for treatment outcome. Schizophr. Res. 2003, 60:117-123.
53. Pfefferbaum A., Ford J.M., White P.M., Roth W.T. P3 in schizophrenia is affected by stimulus modality, response requirements, medication status, and negative symptoms. Arch. Gen. Psychiatry 1989, 46:1035-1044.
54. Pillai Anilkumar, Terry Alvin V., Mahadik Sahebarao P. Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus. Schizophr. Res. 2006, 82:95-106.
55. Polich J. P300 clinical utility and control of variability. J. Clin. Neurophysiol. 1998, 15:14-33.
56. Polich J. Theoretical overview of P3a and P3b. Detection of Change: Event-Related Potential and fMRI Findings 2003, 83-98. Kluwer Academic, Boston. J. Polich (Ed.).
57. Pritchard W.S. Cognitive event-related potential correlates ofschizophrenia. Psychol. Bull. 1986, 100:43-66.
58. Rennie C.J., Robinson P.A., Wright J.J. Unified neurophysical model of EEG spectra and evoked potentials. Biol. Cybern. 2002, 86:457-471.
59. Roth W.T., Cannon E.H. Some features of the auditory evoked response in schizophrenics. Arch. Gen. Psychiatry 1972, 27:466-471.
60. Salisbury D.F., Shenton M.E., Sherwood A.R., Fischer I.A., Yurgelun-Todd D.A., Tohen M., et al. First-episode schizophrenic psychosis differs from first-episode affective psychosis and controls in P300 amplitude over left temporal lobe. Arch. Gen. Psychiatry 1998, 55:173-180.
61. Shen K.F., Crain S.M. Nerve growth factor rapidly prolongs the action potential of mature sensory ganglion neurons in culture, and this effect requires activation of Gs-coupled excitatory kappa-opioid receptors on these cells. J. Neurosci. 1994, 14:5570-5579.
62. Soltani M., Knight R.T. Neural origins of the P300. Crit. Rev. Neurobiol. 2000, 14:199-224.
63. St.Clair D., Blackwood D., Muir W. P300 abnormality in schizophrenic subtypes. J. Psychiatr. Res. 1989, 23:49-55.
64. Strik W.K., Dierks T., Maurer K. Amplitudes of auditory P300 in remitted and residual schizophrenics: correlations with clinical features. Neuropsychobiology 1993, 27:54-60.
65. Takayuki E., Daisuke S., Yoshiyuki W., Kazuyuki I., Sadamitsu H., Masao Y., Kenichi M., Masakazu T., Takashi I. Nerve growth factor and brain-derived neurotrophic factor attenuate angiotensin-II-induced facilitationof calcium channels in acutely dissociated nucleus tractus solitarii neurons of the rat. Archives of Oral Biology 2008, 53:1192-1201.
66. Thoene H. Neurotrophins and neuronal plasticity. Science 1996, 270:593-598.
67. Turetsky B., Colbath E.A., Gur R.E. P300 subcomponent abnormalities in schizophrenia: II. Longitudinal stability and relationship to symptom change. Biol. Psychiatry 1998, 43:31-39.
68. van Beveren N.J.M., van der Spelt J.-J., de Haan L., Fekkes D. Schizophrenia-associated neural growth factors in peripheral blood. A review. European Neuropsychop Harmacology 2006, 16:469-480.
69. Verleger R. Event-related potentials and cognition: a critique of the context updating hypothesis and an alternative interpretation of P3. Behav. Brain Sci. 1998, 11:343-356.
70. Wang J., Hirayasu Y., Hiramatsu K., Hokama H., Miyazato H., Ogura C. Increased rate of P300 latency prolongation with age in drug-naive and first episode schizophrenia. Clin. Neurophysiol. 2003, 114:2029-2035.
71. Wang J., Hirayasu Y., Hokama H., Tanaka S., Kondo T., Zhang M., et al. Influence of duration of untreated psychosis on auditory P300 in drug-naive and first-episode schizophrenia. Psychiatry Clin. Neurosci. 2005, 59:209-214.
72. Williams L.M., Bahramali H., Hemsley D.R., Harris A.W.F., Brown K., Gordon E. Electrodermal responsivity distinguishes ERP activity and symptom profile in schizophrenia. Schizophr. Res. 2003, 59:115-125.
73. Zhang M., Chen X. Brain Potential 1997, Shanghai Technical and Education Press, Shanghai, pp. 265-266. second ed.